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Abstract
Introduction: Heterogeneity in risk of conversion to Alzheimer’s disease (AD) among individuals with mild cognitive
impairment (MCI) is well known. Novel statistical methods that are based on partially ordered set (poset) models can
be used to create models that provide detailed and accurate information about performance with specific cognitive
functions. This approach allows for the study of direct links between specific cognitive functions and risk of
conversion to AD from MCI. It also allows for further delineation of multi-domain amnestic MCI, in relation to specific
non-amnestic cognitive deficits, and the modeling of a range of episodic memory functioning levels.
Methods: From the Alzheimer’s Disease Neuroimaging Initiative (ADNI) study, conversion at 24 months of 268 MCI
subjects was analyzed. It was found that 101 of those subjects (37.7%) converted to AD within that time frame.
Poset models were then used to classify cognitive performance for MCI subjects. Respective observed conversion
rates to AD were calculated for various cognitive subgroups, and by APOE e4 allele status. These rates were then
compared across subgroups.
Results: The observed conversion rate for MCI subjects with a relatively lower functioning with a high level of
episodic memory at baseline was 61.2%. In MCI subjects who additionally also had relatively lower perceptual
motor speed functioning and at least one APOE e4 allele, the conversion rate was 84.2%. In contrast, the observed
conversion rate was 9.8% for MCI subjects with a relatively higher episodic memory functioning level and no APOE
e4 allele. Relatively lower functioning with cognitive flexibility and perceptual motor speed by itself also appears to
be associated with higher conversion rates.
Conclusions: Among MCI subjects, specific baseline cognitive profiles that were derived through poset modeling
methods, are clearly associated with differential rates of conversion to AD. More precise delineation of MCI by such
cognitive functioning profiles, including notions such as multidomain amnestic MCI, can help in gaining further
insight into how heterogeneity arises in outcomes. Poset-based modeling methods may be useful for providing
more precise classification of cognitive subgroups among MCI for imaging and genetics studies, and for
developing more efficient and focused cognitive test batteries.
Introduction
There is increasing interest in the recognition and treat-
ment of prodromal stages of Alzheimer’s disease (AD),
especially mild cognitive impairment (MCI). MCI is
viewed as a state between normal cognitive functioning
and dementia. Those with MCI are characterized as
exhibiting mild problems with memory and/or other
cognitive functions, while still being able to perform
daily life activities normally or nearly so [1]. Despite
having a higher overall risk of developing AD [1], con-
version outcomes among those with MCI are quite het-
erogeneous. Only about 15% of these individuals convert
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to AD per year; many never convert, and some revert to
normal cognition [2]. This heterogeneity makes it diffi-
cult to design efficient trials of agents designed to delay
or prevent progression from MCI to AD or to interpret
the outcomes of these trials [3], or to evaluate potential
AD biomarkers. Hence, there is a clear need to better
delineate cognitive phenotypes in MCI.
Although MCI subgroups that reflect deficit heteroge-
neity, such as amnestic single domain MCI, amnestic
multidomain MCI, and non-amnestic multidomain MCI
[4] have been developed, they lack specificity in the par-
ticular cognitive functions that are impaired in each
subgroup. This type of specification is challenging
because neuropsychological (NP) response data are
complex. It can be difficult to isolate a deficit in a parti-
cular cognitive function, since performing well on most
NP measures requires tapping into several cognitive
functions, and it is often not possible to design tests
that tap one cognitive domain to the exclusion of all
others. For example, it is possible to perform poorly on
a verbal list-learning task as a result of impaired atten-
tion or word fluency, and in the absence of an amnestic
disturbance. Hence, if an individual performs poorly on
a given measure, it may be difficult to pinpoint exactly
which function is impaired.
Subscales are commonly used in an attempt to improve
specificity in analysis of NP assessment data. For
instance, subscales can be derived from factor analysis
through the use of factor scores. However, scale-based
approaches are generally limited by the assumption of a
direct correspondence between a subscale score and an
associated function. Poor performance on a subscale is
interpreted as indicating a deficit in the function the sub-
scale is purported to measure, even if the poor perfor-
mance is due to deficits in functions not associated with
the subscale. This makes it difficult to link NP test
performance to specific functional deficits, and hence to
identify cognitive phenotypes that can be linked to out-
comes such as conversion from MCI to AD.
Use of total scores on multi-item measures, such as the
Alzheimer’s disease assessment scale-cognitive (ADAS-
Cog) measure [5] or the mini-mental status exam
(MMSE) [6], as a basis for cognitive phenotyping is also
problematic. Total scores represent a (weighted) sum of
response scores from items assessing several cognitive
domains. However, the same total score can be derived
from a range of different response patterns, without
regard to the cognitive functions being assessed by each
item. In this sense, items are viewed as interchangeable,
even though the cognitive targets of assessment for the
items can vary considerably. Because a wide range of
response patterns and cognitive interpretations can give
rise to the same score, resulting phenotypes lack
specificity.
The partially ordered set (poset) modeling approach to
interpreting NP data
Poset models serve as a basis for novel methods tailored
for classifying the performance (that is, functioning)
levels of subjects with respect to specific cognitive func-
tions. Classification is conducted based on observed
responses to NP measures. Each measure is associated
with specific cognitive functions that are involved in per-
forming well on that measure, so that the ties between
observed responses and functioning levels are clear. This
approach is feasible because posets have essential statisti-
cal convergence properties such as assuring that a sub-
ject’s state is identified accurately with sufficient
measurement, even in the presence of measures that are
associated with multiple functions. Theoretically derived
validation tools are available as well. Statistical theory
and data-analytic frameworks for the poset approach
have been established in Tatsuoka and Ferguson (2003)
[7] and Tatsuoka (2002) [8].
In this paper, our goal is to demonstrate that posets
can improve our understanding of MCI heterogeneity.
The modeling results in the development of states asso-
ciated with profiles of cognitive functioning that sum-
marize performance levels for each of the cognitive
functions being tested by a given NP battery. Hence, a
state can be viewed as similar to a diagnostic classifi-
cation in which the diagnosis represents a particular pat-
tern of cognitive strengths and weaknesses. States are
ordered by comparing the associated performance levels
for each of the functions included in the analysis. One
state is considered greater than a second state if its asso-
ciated performance level on at least one function is
strictly higher than the performance level for the second
state, and its performance levels for all other functions
are at least as high. However, posets are flexible in that it
is not necessary that one state be greater than another, in
other words, the states can be partially ordered. This
arises when one state in comparison to another state has
a higher performance level with respect to one function,
while having a lower performance level with respect to
another function. This enables models to reflect a com-
plex range of responses from an NP battery.
A probability distribution on the states is used to
represent belief about which state best describes the
cognitive capabilities of a subject. Bayes’ rule is used to
obtain updated posterior probabilities of state member-
ship once responses to measures are observed. This
allows for a systematic manner in which the information
obtained from observing multiple measures can be com-
bined for statistical classification. Two response distribu-
tions are estimated per NP measure, one representing
the response tendencies of subjects who perform at a
relatively high level on all functions associated with the
particular measure and another for those subjects who
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do not. These distributions are used to weigh the rela-
tive likelihood of an observed response indicating that a
subject has the associated higher level functioning. The
approach of estimating two response distributions per
NP measure is parsimonious in that there is no need to
estimate response distribution parameters that are specific
to each profile; rather, response distribution parameters
are shared either by profiles that have the associated func-
tioning levels, or those that do not. Ideally, one state in the
model will have a probability close to 1 for each individual,
while other states will have probabilities near 0, indicating
that a subject’s cognitive profile is known with near cer-
tainty. As long as models are correctly specified, this near
certainty will indeed be obtained given a sufficient amount
of testing [7]. Once classification is completed, subjects
who share a cognitive profile can be aggregated, and
observed rates of conversion to AD between the resulting
subgroups can be compared.
In our study, we usedNP data collected by the Alzheimer’s
Disease Neuroimaging Initiative (ADNI) [9] to evaluate
the usefulness of poset models to identify specific cogni-
tive phenotypes associated with conversion from MCI to
AD [7,8,10,11]. We hypothesized that poset modeling
would generate interpretable and sufficiently detailed
cognitive phenotypes with clearly differentiated rates of
conversion from MCI to AD. Given its established
importance in progression risk for AD, Apolipoprotein
E (APOE) e4 status was also taken into account [12,13].
Materials and methods
Study sample
MCI subjects enrolled in the ADNI (n = 389) were
included in the classification analysis if their scores on
the selected NP battery were available at both baseline
and at 24 months. The sample was 64.5% male and 93.1%
Caucasian. About 3.8% were African American, 2.8%
were Asian, and 0.3% were American Indian or Alaskan
Native. Mean age was 74.8 years (SD = 7.5) and mean
length of education was 15.7 years (SD = 3.0).
Modeling and classification approach
We used neuropsychologist expert opinion (JJ and HYT)
to map the relationship between selected ADNI NP
measures (ADAS delayed recall and word recognition
subscales and number cancellation; auditory verbal
learning test (AVLT) Trial 6 and List B; Boston naming
test; category fluency; trail making Test A and Test B,
and Wechsler adult intelligence scale-revised (WAIS-R)
digit symbol substitution) and the cognitive functions
required to perform them (episodic memory at four dif-
ferent levels, word fluency, cognitive flexibility, percep-
tual motor speed, and attention). See Table 1 for the
listing of these specifications. Measures were selected
based on the types of functions they tested and retained
based on statistical criteria such as discriminatory prop-
erties and correspondence with model fit. Given the reli-
ance on expert opinion, data-analytic validation is
important. Statistical details on how this validation was
performed are provided in Additional file 1 (Appendix).
To acknowledge the key role of episodic memory
impairment as an early symptom in AD and to better
represent the varying levels of episodic memory required
across the measures, we identified four levels of episodic
memory proficiency (levels 0 through 3). These levels
are ordered in terms of episodic memory demand, with
level the highest, and level 0 the lowest. Level 3
Table 1 Cognitive functions and how they are tapped into by selected ADNI neuropsychology measures, as specified
according to expert opinion





















AVLT-Trial 6 X X X X
AVLT-List B X X X
Boston naming test X X




Trail making test A X X




ADAS, Alzheimer’s Disease Cooperative Study; ADNI, Alzheimer’s Disease Neuroimaging Initiative; AVLT, adult verbal learning test; WAIS-R, Wechsler adult
intelligence scale-revised; *average of vegetable and animal categories.
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corresponds to relatively longer-term delayed recall with
distractors, while level 2 and level 1, respectively, relate
to shorter and shorter recall durations involved in
AVLT List B and immediate recall. A subject at level 0
cannot perform well at any of the other levels. A brief
summary of the practical interpretation of the episodic
memory levels to be used here is given in Table 2.
Through the assumed hierarchical ordering between
levels of episodic memory, note that the delayed recall
measures that involve level 3 also can provide information
on functioning with levels 1 and 2. High functioning at
level 3 implies high functioning at levels 1 and 2 as well.
Also, poor performance on word recognition, which is
associated with level 1, not only provides evidence that
level 1 is at a low level, but that functioning at levels 2 and
3 should be low as well. Hence, even though associations
of measures involving episodic memory can be at different
levels, they still can inform other levels of episodic mem-
ory functioning, affording some degree of replication.
Poset model generation
A poset model was generated based on the functions asso-
ciated with each of the ADNI NP measures. In the cogni-
tive profiles associated to states in the model, performance
levels for a function were denoted either as relatively high,
or relatively low, in relation to the MCI and early AD
sample. See Table 3 for a complete list of profiles that can
Table 2 Description of episodic memory functioning
levels used in the model
Level Description
Level 3 Relatively longer-term delayed recall with distractors
Level 2 Relatively shorter recall durations, such as involved in AVLT List B
Level 1 Immediate recall, word recognition
Level 0 Cannot perform well at any of the above levels
AVLT, adult verbal learning test
Table 3 Poset states and their corresponding profiles of cognitive functioning relative to mild cognititve impairment
and Alzheimer’s disease















1 X X X X X X X
2 X X X X X X
3 X X X X X X
4 X X X X X
5 X X X X X X
6 X X X X X
7 X X X X * X
8 X X X X X X
9 X X X X X
10 X X X X X
11 X X X X
12 X X X X X
13 X X X X
14 X X X *
15 X X X X X
16 X X X X
17 X X X X
18 X X X
19 X X X X
20 X X X
21 X X *
22 X X X X
23 X X X
24 X X X
25 X X




X indicates relatively high functioning; *undetermined..
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be distinguished by the given set of NP measures that were
analyzed.
The resultant poset model comprised 29 states. These
states (and associated cognitive profiles) represent the
profiles that can be distinguished from the NP battery,
and were identified algorithmically from the expert-
derived specifications in Table 1 [14]. Table 3 shows
how the cognitive functions we examined are distributed
across states to create distinct cognitive profiles. The
corresponding partial ordering of these profiles is gra-
phically depicted in Figure 1 as a Hasse diagram. Note
that state 1 is the highest state in the poset, as it has the
highest level of functioning for all five cognitive func-
tions. State 29 is the lowest state, since all its function-
ing for all five functions is at the lowest level. For the
in-between states, there exists at least one function for
which performance is not at a relatively high level. In


























Figure 1 Partially ordered set (poset) model for cognitive functioning of mild cognifitive impairment and early Alzheimer’s disease
subjects.
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direct ordering, with the higher of the states being
greater than the lower one.
In our analysis, a uniform prior probability value of 1/29
was assigned to each state for each subject to indicate
prior belief about which profile would fit a given subject.
We then estimated two response distributions for each NP
measure as described above. These distributions were then
used to weigh the relative likelihood that an observed
response indicated that a subject had the associated higher
level functioning.
Response distributions
Responses from both the MCI subjects and also early AD
subjects (an additional 174 such subjects) were included
in the estimation, to allow for a range of values. Given
the apparent non-normality of response data, nonpara-
metric approaches to response distribution estimation
were adopted [10,11,15-17] (see Additional file 1).
Grouping of profiles and classified subjects
The ordered relationships between states arise when
identifying subgroups with shared functioning levels for
a function. For instance, the subgroup of states that
have high performance level for episodic memory level 2
are all the states greater than or equal to state 14. Pre-
cisely, this would be state 1 through 12, and state 14.
The complement of this subgroup (all states not greater
than or equal to state 14) would thus comprise the
states with lower performance level. Once subgroups
such as this have been identified and classification con-
ducted, the probability that a subject has a particular
performance level for a function can be computed by
summing the posterior probabilities of membership of
each of the states in the subgroup. These probabilities
are used as a basis for cutoff values in function-related
groupings, which are then compared statistically in
terms of proportion of AD conversions from MCI. All
reported P-values are two-sided.
We treated cognitive flexibility slightly differently from
other NP functions, due to confounding of its functioning
status in classification under certain profiles, specifically
for states 7, 14, 21, and 28. Confounded profiles arise due
to limitations of the NP battery to distinguish all possible
profiles. Profiles with confounding give conflicting infor-
mation about certain functions, but probabilities for a
subject being at certain functioning levels can still be
obtained by weighting the information provided across a
set of confounded profiles (see Additional file 1 for more
details).
Model validation
Briefly, model fit appears to be good. Response distribu-
tion estimates for all measures correspond to the assumed
order structure, in that those subjects expected by the
model to score well actually tended to do so, and those
not expected to score well tended not to do so. Moreover,
classification was fairly decisive, especially given the
limited number of NP measures employed. Observed
responses to the measures were thus consistent with
the model specifications. See Figures S1 through S6 and
Table S1 in Additional file 1.
Results and discussion
We explored different cognitive groupings within MCI
subjects, to assess conversion rates to AD at two years
post baseline. Not surprisingly, episodic memory is the
cognitive function that appears to be most significantly
related to future conversion. Still, the different perfor-
mance levels of episodic memory in our model appear
to have varying degrees and ways of association with
conversion outcomes. For instance, as seen in Table 4,
level 2 episodic memory performance levels influence
the rate of conversion among those with MCI. In sub-
jects for whom level 2 episodic memory functioning is
low (in other words, below the cutoff probability value
of less than 0.275), 41 out of 67 (61.2%±11.7%, 95% CI)
converted to AD within two years, which is much higher
than the overall MCI to AD conversion rate in this sam-
ple of 101 out of 268 (37.7%±5.8%, 95% CI). Those with
relatively lower performance in level 2 of episodic mem-
ory significantly differ in conversion rates compared
with those with higher performance, regardless of
whether or not the APOE e4 allele is present. The
P-value for Fisher’s exact test is 0.000 for a two-sided
test of no association between conversion and having
relatively low episodic memory level 2 functioning.
Other functions where relatively lower functioning at
baseline may indicate higher risk for conversion from
MCI to AD are perceptual motor speed and cognitive
flexibility. For perceptual motor speed, using a cutoff
Table 4 Relationship between episodic memory level 2 functioning and conversion to Alzheimer’s disease (AD) over a
two-year period
Converted to AD Low episodic memory level 2 function Not low episodic memory level 2 function Total
Yes 61.2% (41) 29.9% (60) 37.7% (101)
No 38.8% (26) 70.1% (141) 62.3% (167)
Total 100% (67) 100% (201) 100% (268)
Results are presented as the percent (number) of patients. Fisher’s exact test two-sided P-value = 0.000 for a test of no association; positive predictive value = 0.612;
negative predictive value = 0.701.
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probability value of 0.40 to delineate a lower functioning
subgroup, and considering subjects with at least one
APOE4 allele, 23 of 35 (65.7%±15.7%, 95% CI) of MCI
subjects with relatively low functioning convert to AD
within 24 months. On the other hand, only 14 of 35
MCI subjects with relatively low perceptual motor speed
and without an APOE4 allele convert (40%±16.2%, 95%
CI). Further, for cognitive flexibility, using a cutoff prob-
ability value of 0.30 to delineate a lower functioning
subgroup, 28 of 48 (58.3%±13.9%, 95% CI) of MCI sub-
jects with relative low baseline functioning convert to
AD within 24 months. In this case, the P-value for Fish-
er’s exact test of no association is 0.007.
Interestingly, we conversely found much lower rates of
conversion among certain cognitive profiles. In particu-
lar, only four out of forty-one (9.8%±9.1%, 95% CI) MCI
subjects with no APOE e4 alleles and relatively high
level-3 episodic memory functioning (cutoff probability
value greater than 0.80) convert in two years. This rate
appears to be lower than for subjects with no APOE e4
allele but without high level-3 episodic memory function-
ing (P-value = 0.001, Fisher’s exact test of no association).
Amnestic multidomain MCI identified with poset models
An advantage of the poset approach is the ability to pro-
vide classification to profiles that address a range of func-
tions. Subgroups, such as amnestic multidomain MCI, can
be characterized more precisely by identifying specific
functions that are relatively impaired along with episodic
memory.
In our sample, subjects with relatively low functioning
on episodic memory level 2 (probability of being at high
level at level 2 being 0.275 or less) and perception speed
(probability cutoff value of 0.40 or less) were identified.
As shown in Table 5, among subjects with at least one
APOE e4 allele and with relatively low levels of both
episodic memory and perception speed, 16 out of 19
converted (84.2%±16.4%, 95% CI). Considering only sub-
jects with lower level-2 episodic memory functioning,
those who additionally have lower functioning in per-
ceptual motor speed appear even more likely to convert
(P-value = 0.013, Fisher’s exact test of no association).
In contrast, additionally having lower functioning with
cognitive flexibility did not appear to significantly
increase risk for conversion. Among subjects with lower
episodic memory level 2 functioning, observed percen-
tages of conversion with and without lower cognitive
flexibility were 66.7% versus 57.5% (18 out of 27 versus
23 out of 40).
Cognitive change before conversion
Over the range of cognitive functions, histograms were
generated for the respective probabilities of converters
having relatively high functioning over the 24 months
preceding conversion. Analogous histograms were gen-
erated for non-converters over a time period of the
same duration starting from baseline. See Figures 2, 3, 4,
5, 6, 7, 8. Note that for non-converters, only those sub-
jects who did not convert over the full 36-month period
of the study were included in the plots. By comparing
corresponding plots between converters and non-con-
verters, it becomes clearer how the above findings of
heterogeneity in conversion outcomes by cognitive pro-
file arose.
For Figures 2, 3, 4, which correspond to the episodic
memory levels, note that relative to level 2, level 1 does
not see the same amount of decline over 24 months for
converters, as reflected by a shift to lower probability
values. Hence, the discrepancy between the histograms
in Figures 2a versus 2b over time between converters
and non-converters is not very strong. On the other
hand, in Figures 3a and 3b, it is clear that for conver-
ters, there is quite a bit of decline in level 2 values dur-
ing this time period, while non-converters appear stable.
This makes level 2 attractive for discrimination and pre-
diction over this duration. In Figures 4a and 4b, note
that level 3 functioning is low among almost all conver-
ters preceding conversion. However, lower functioning
for this more difficult level also is common for non-con-
verters, lessening the discriminatory properties of level
3. Still, there is a sizeable proportion of non-converters
retaining high probability values for level 3, which
allows for cognitively-based identification of a very low-
risk group.
Table 5 Relationship between episodic memory level 2 and perceptual motor speed functioning and conversion to AD
over a two-year period by APOE4 allele status
Converted to
AD
Low episodic memory function and no
APOE4 allelea











Yes 63.6% (7) 54.5% (6) 59.1% (13) 84.2% (16) 37.8% 17) 61.2% (18)
No 36.4% (4) 45.5% (5) 40.9% (9) 15.8% (3) 62.2% (28) 38.8% (10)
Total 100% (11) 100% (11) 100% (22) 100% (19) 100% (13) 100% (28)
Results are presented as the percent (number) of patients.aFisher’s exact test two-sided P-value = 1.00 for a test of no association. bFisher’s exact test two-sided
P-value = 0.013 for a test of no association. AD, Alzheimer’s disease; APOE, Apolipoprotein.
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Figures 2 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with episodic memory level 1 from 24 to 0 months before conversion to AD
among MCI subjects. Respectively, n = 75, 75, 68, 51, and 36 for 0, 6, 12, 18 and 24 months before conversion. (b) Probability of relatively high
functioning with episodic memory level 1 from baseline (0 months) to 24 months among MCI subjects who did not convert within 36 months; n = 90.
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Figure 3 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with episodic memory level 2 from 0 to 24 months before conversion to AD
among MCI subjects. (b) Probability of relatively high functioning with episodic memory level 2 from baseline to 24 months among MCI subjects
who did not convert within 36 months.
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 (a)
(b)
Figure 4 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with episodic memory level 3 from 24 to 0 months before conversion to AD
among MCI subjects. (b) Probability of relatively high functioning with episodic memory level 3 from baseline to 24 months among MCI subjects
who did not convert within 36 months.
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(a)
(b)
Figure 5 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with word fluency from 24 to 0 months before conversion to AD among MCI
subjects. (b) Probability of relatively high functioning with word fluency from baseline to 24 months among MCI subjects who did not convert
within 36 months.
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Figure 6 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with attention/sustained vigilance from 24 to 0 months before conversion to
AD among MCI subjects. (b) Probability of relatively high functioning with attention/sustained vigilance from baseline to 24 months among MCI
subjects who did not convert within 36 months.
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Figure 7 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with cognitive flexibility from 24 to 0 months before conversion to AD
among MCI subjects. (b) Probability of relatively high functioning with cognitive flexibility from baseline to 24 months among MCI subjects who
did not convert within 36 months.
Tatsuoka et al. Alzheimer’s Research & Therapy 2013, 5:14
http://alzres.com/content/5/2/14




Figure 8 Probabilities of functioning over time among mild cognitive impairment (MCI) converters to Alzheimer’s disease (AD) versus
MCI non-converters. (a) Probability of relatively high functioning with perceptual motor speed from 24 to 0 months before conversion to AD
among MCI subjects. (b) Probability of relatively high functioning with perceptual motor speed from baseline to 24 months among MCI subjects
who did not convert within 36 months.
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In Figures 5a and 5b, it appears that there may be
decline in word fluency values for a relatively small subset
of subjects as they near conversion, but many converters
also appear to retain high functioning. For non-converters,
some subjects have lower functioning as well. Hence,
word fluency does not appear useful for predicting conver-
sion within a two-year period. In Figures 6a and 6b, note
that there may be some slight decline in attention/
sustained vigilance for converters, but almost all subjects
still retain high probability values for being at a high level
of attention functioning.
In Figures 7a and 7b, there is definitely a fair amount
of decline in values for cognitive flexibility among con-
verters, although it is also not as pronounced as for epi-
sodic memory level 2. Also, some converters retain high
functioning. Most non-converters retain high function-
ing over the duration. Hence, cognitive flexibility can be
useful for discriminating future conversion outcomes,
but does not appear as informative as episodic memory
level 2. Finally, in Figures 8a and 8b, for perceptual motor
speed, note that there appears to be a subset of converters
for whom perceptual motor speed becomes more
impaired. While there are non-converters who also have
low probability values, this number is outweighed by the
converters over the duration. Moreover, as Table 5 indi-
cates, these converters are likely to also be relatively more
impaired with episodic memory level 2 than the non-
converters. This allows us to identify this particular com-
bination of lower level functioning as being specifically
associated with high risk for conversion.
Multivariate prediction using logistic regression models
A multivariate model was fit that recognized the above
findings, and included other variables such as gender,
age, and educational level. The presence of an APOE4
allele was viewed as a binary variable, as well as whether
or not a subject had attended college. Also, probability
values for performing at a relatively high level for episo-
dic memory level 2, cognitive flexibility, and perceptual
motor speed were viewed as continuous explanatory
variables. After an initial fit of a full model, gender, age,
and educational level were clearly not significant predic-
tors in the model (respective P-values were 0.96, 0.65,
and 0.81; Wald’s test). Using goodness-of-fit tests based
on the test statistic of -2 times the difference in log-
likelihood values to compare nested models, it appears
the best fit is when episodic memory level 2, perceptual
motor speed, and APOE4 status are included in the
model. Results are given in Table 6. Note that episodic
memory level 2, perceptual motor speed, and APOE4
status all are significant predictors (P-value <0.05;
Wald’s test). When cognitive flexibility is included with
these variables, it is not significant (P-value = 0.26).
Using the model-based estimated probabilities of con-
verting to AD as a predictor, and for instance, using a
cutoff value of 0.55 or higher, classification accuracy is
66.8%, with positive predictive value of 61.5% (32 out of
52). Figure 9 displays receiver operating characteristic
(ROC) curves for these logistic regression probabilities,
as well as for the probabilities for episodic memory level
2, perceptual motor speed, and cognitive flexibility.
Values for the area under the curve (AUC) are 0.710,
0.678, 0.655, and 0.644, respectively. Using a multivari-
ate approach can thus apparently improve prediction.
However, compared to relying upon episodic memory
level 2 alone without the need for APOE4 status infor-
mation, which would have practical appeal, the differ-
ence does not appear to be striking.
Other prediction approaches
A comprehensive review of research efforts using ADNI
data is given in Weiner et al. (2012) [18]. This includes
a description of work on prediction of MCI to AD con-
version. Taking advantage of the richness of the ADNI
data, prediction models have been developed based on a
range of various imaging, cerebrospinal fluid, and
genetic biomarkers, as well as cognition. Our prediction
results appear to be comparable to non-cognitively
oriented methods that rely on baseline data [19,20].
Advantages of a cognitive testing approach include non-
invasiveness and cost, especially if focused and efficient
NP batteries can be designed, and computer-based
adaptive testing adopted in the future.
Other cognitive testing-based approaches to prediction
include Tabert et al. (2006) [21] and Fleisher et al.
(2007) [22]. Their prediction models depend directly on
NP measurement scores, which in general may be diffi-
cult to interpret in terms of identifying which cognitive
functions may be the source of poor scores. We believe
that the results presented here add to these works, such
as through a more specific consideration of multidomain
MCI. Poset-based methods also provided insight into
Table 6 Multivariate logistic regression model with
outcome as conversion to Alzheimer’s disease (AD) from
mild cognitive impairment (MCI) within 24 months from
baseline
Explanatory variables B Wald test P-value Exp (B)
APOE4 0.623 0.024 0.536
Episodic memory level 2 -1.445 0.001 0.236
Perceptual motor speed -0.926 0.009 0.396
Intercept 1.193 0.000 3.298
Dependent variable value of 1 indicates that a subject has converted to AD
from MCI within 24 months of baseline. Binary variable Apolipoprotein (APOE)
4 = 1 indicates that the subject has at least one APOE4 allele and higher risk
for conversion. Larger probability values of relatively high performance
indicate lower risk for conversion.
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the course of cognitive change in MCI, by indicating
how specific functions are affected over time. The find-
ings depicted in Figure 4 allow for insight into the het-
erogeneity in cognitive progressions that arise among
MCI, and thus help in identifying profiles of high risk.
Conclusions
Our results suggest the utility of the poset-based
approach in uncovering heterogeneity in risk for conver-
sion from MCI to AD by generating subgroups tied to
specific cognitive functions. Duration of 24 months
from baseline measurement was considered. Among the
cognitive functions evaluated, episodic memory was
mostly strongly linked to conversion from MCI to AD.
This confirms similar findings in Tierney et al. (2005)
[23], Tabert et al. (2006) [21], Blacker et al. (2007) [24],
and Landau et al. (2010) [18]. We did find that cognitive
flexibility and perceptual motor speed also is associated
with conversion, as certain subjects are apparently
affected in these domains during the 24 months preced-
ing conversion. Conversely, MCI subjects with relatively
less episodic memory impairment were observed to con-
vert at a much lower rate. The importance of the APOE
e4 allele in affecting risk for conversion is also clear
[18,19].
More precisely, it appears that in our model certain
levels of episodic memory functioning are more discri-
minatory than others in terms of identifying MCI sub-
jects at especially high risk for conversion. In particular,
level-2 episodic memory functioning, more so than
level-3, appears to best identify risk for conversion. It
appears that delayed recall with distractors may be too
difficult a task to discriminate risk very well. On the
other hand, for those that can perform well at level 3
relative to others with MCI, risk of conversion is much
lower, as illustrated in Table 5.
Poset modeling also appears to be helpful in further
clarifying the notion of multidomain MCI. Our analyses
suggest that perceptual motor speed functioning may
have a stronger link to subsequent risk of AD progres-
sion than other cognitive functions when considered in
conjunction with relatively reduced function of level-2
Figure 9 Area under the curve (AUC). Multivariate logistic model probability values for conversion = 0.710, episodic memory level 2
probability of high functioning = 0.678, perceptual motor speed probability of high functioning = 0.655, cognitive flexibility probability of high
functioning = 0.644.
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episodic memory. On the other hand, additional impair-
ment with cognitive flexibility does not appear to
increase risk beyond that due to episodic memory
impairment. These results suggest that having relatively
lower functioning across multiple functions can indeed
increase risk for AD, but, that it may matter which of
the functions are impaired. Because corresponding sam-
ples become smaller as specific combinations of deficits
are analyzed, however, these analyses must be viewed as
preliminary.
A possible concern is that the ranges of performance
levels for functions in the poset model are limited, parti-
cularly when a functioning level is either high or low.
However, it should be kept in mind that there are also
limited NP response data available, due to the time-con-
suming and burdensome nature of NP measurement.
Hence, there are statistical limitations to the granularity
of information on functioning that can be assessed accu-
rately. Our model was shown to be feasible, while still
being able to provide discriminating information relating
to AD conversion. Another limitation is the scope of
inference that can be made from the ADNI sample,
which was overwhelmingly Caucasian, and imbalanced
towards males. Certainly, these findings should be vali-
dated in other datasets.
Future directions
Since the poset model allows for precise and detailed
cognitive profiles, this approach can be used in conjunc-
tion with imaging and genetic studies. As an example, a
cluster analysis approach has recently been applied to
characterize MCI subgroups by cognitive characteristics
[25]. While white matter lesion burden was found to
differ by these groupings, in general, cognitive subtypes
resulting from cluster analysis can at times be more dif-
ficult to interpret than profiles generated with poset
models. Also, note the persistent heterogeneity of con-
version outcomes among MCI subjects even within the
cognitively homogeneous subgroups generated here.
These subgroups could be an interesting basis for func-
tional magnetic resonance imaging (fMRI) studies of
cognitive reserve, which may improve understanding of
how this heterogeneity arises [26,27]. Poset modeling
may also be useful in clinical trial design, as enriched
sampling from subgroups of MCI subjects that have
high positive predictive value of conversion could reduce
sample size requirements.
Finally, poset models can serve as a basis for adaptive
NP testing, with NP measures being selected for admin-
istration dynamically, based on the responses that have
already been observed [7,8]. As demonstrated, an attrac-
tive feature of poset models is that since they are com-
prised of discrete states, accurate statistical classification
can be conducted with relatively few measures. Adaptive
tests can further reduce subject burden and allow for
more focused and efficient testing, which in turn would
enhance the appeal of cognitive testing for prediction.
Additional material
Additional file 1: Appendix: Statistical framework for data analysis
and model validation. This file contains statistical details relating to the
poset modeling, including parameter estimates and classification
summaries. It also describes how model validation was conducted.
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